A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in
combination with tremelimumab on this type of cancer. In addition, this study will look at
the side effects of durvalumab when given alone or in combination with tremelimumab.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society